Lunai Bioworks Regains Compliance with Nasdaq Minimum Bid Price Requirement
On June 11, 2026, Lunai Bioworks, Inc. received formal notification from The Nasdaq Stock Market LLC confirming that the company has regained compliance with Nasdaq Listing Rule 5550(a)(2). This rule requires listed securities to maintain a minimum bid price of at least $1.00 per share. The company has satisfied the conditions previously set forth in the Nasdaq Hearings Panelβs decision and subsequent extension letters from April and May 2026. As a condition of regaining compliance, the company will be subject to a mandatory Panel monitor for a period of one year. During this monitoring period, if the company falls out of compliance with the minimum bid price requirement again, it will not be eligible for the standard cure periods or the opportunity to submit a compliance plan. Instead, Nasdaq staff would issue an immediate delist determination letter, although the company would retain the right to request a new hearing to stay any delisting action. This resolution successfully closes the immediate threat of delisting for the company's common stock (LNAI).